 To examine the efficacy and safety of aripiprazole versus placebo as an adjunctive therapy co-administered with either an selective serotonin reuptake inhibitor SSRI or a serotonin-norepinephrine reuptake inhibitor SNRI in patients with major depressive disorder. 